PSNL
Personalis·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PSNL
Personalis, Inc.
A leading provider of advanced genomics and AI-powered precision medicine solutions for cancer and rare genetic disorders
Life Science Tools and Services
02/21/2011
06/20/2019
NASDAQ Stock Exchange
228
12-31
Common stock
6600 Dumbarton Circle, Fremont, California 94555
--
Personalis, Inc., was incorporated in Delaware on February 21, 2011 and commenced operations in September 2011. The company is a growing cancer genomics company that transforms the development of next-generation therapies by providing more comprehensive molecular data on each patient's cancer and immune response. The company designs its NeXT platform to accommodate the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all approximately 20,000 human genes as well as the immune system, while many cancer groups cover approximately 50 to 500 genes. They are also developing a supplementary liquid biopsy analysis that analyzes all human genes with the more focused liquid biopsy analysis currently available. By combining technological innovation, operational scale and regulatory differentiation, their NeXT platform is designed to help their clients gain new insights into treatment response and resistance mechanisms as well as new potential treatment targets.
Earnings Call
Q1/2025
Estimate EPS-0.25
Actual EPS-0.18
Estimate Revenue17.41M
Actual Revenue20.61M
Personalis Q1 2025: Key Contradictions Unveiled in Reimbursement Strategies, Margins, and Growth Plans
May 07,2025 07:26
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.24
Actual EPS-0.23
Estimate Revenue20.11M
Actual Revenue17.20M
Personalis' Q2 2025 Earnings Call: Dissecting Contradictions in Revenue Projections and Reimbursement Strategies
Aug 05,2025 10:58
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
PSNL has released its 2025 Q3 earnings. EPS was reported at -0.24, versus the expected -0.27, beating expectations. The chart below visualizes how PSNL has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
PSNL has released its 2025 Q3 earnings report, with revenue of 14.49M, reflecting a YoY change of -43.62%, and net profit of -21.65M, showing a YoY change of 44.61%. The Sankey diagram below clearly presents PSNL's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
